Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Accounting policies (Tables)

v3.22.1
Accounting policies (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure of voluntary change in accounting policy [abstract]  
Schedule of interests subsidiary undertakings

The Company has the following interests in subsidiary undertakings:

Name   Country of incorporation  

 

Holding

  Proportion held   Nature of business
TC BioPharm Limited   United Kingdom   Ordinary £1 shares and A Ordinary £0.001 shares   100%   Biotechnology research and development
TC BioPharm (North America), Inc.   United States of America   Ordinary $0.01 shares   100% by TC BioPharm Limited   Biotechnology research and development
TC BioPharm BV   The Netherlands   Ordinary €1 shares   100% by TC BioPharm Limited   Biotechnology research and development
Schedule of expected useful lives for property, plant and equipment

Depreciation is provided at rates intended to write down the cost of the assets over their expected useful lives, as follows;

 

Facility & scientific equipment - 4 to 10 years
Computer equipment - 3 years
Office equipment - 5 years